TG Therapeutics shares rise after its multiple sclerosis drug Briumvi outperforms expectations and shows expanded market potential.
TG Therapeutics (NASDAQ:TGTX) closed at $57.12 on July 10, 2026, reflecting a market capitalization of $8.74 billion. The stock posted a 13.56% one-month return and a 46.76% gain over the past year, driven by stronger-than-expected performance of its key drug, Briumvi.
The company’s focus on therapies for multiple sclerosis saw positive clinical data for a subcutaneous version of Briumvi, which could broaden its addressable market. Hedge fund ownership of TGTX increased to 42 portfolios in Q1 2026, up from 40 in the prior quarter.
ClearBridge SMID Cap Growth Strategy highlighted TGTX as a top contributor in Q2 2026, citing its role in the biotechnology sector’s outperformance.